Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer

Kazuhiko Shiena, Hiromasa Yamamoto, Junichi Sou, Shinichiro Miyoshi, Shinichi Toyooka

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal growth factor receptor (EGFR) was defined as a clinically distinct molecular group. These lesions show oncogene addiction to EGFR and dramatic responses to the EGFR tyrosine kinase inhibitors (TKIs). Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy. However, the long-term effectiveness of EGFR-TKIs is usually limited because of acquired drug resistance. To overcome this resistance to EGFR-TKIs, it will be essential to identify the specific mechanisms underlying the resistance. Many investigators have attempted to identify the mechanisms using preclinical models and drug-resistant clinical samples. As a result, several mechanisms have been showed to be responsible for the resistance, but not all of the relevant mechanisms have been uncovered. In this review, we provide an overview of mechanisms underlying drug-resistance to EGFR-TKIs, focusing on results obtained with preclinical models, and we present some possible strategies to overcome the EGFR-TKI resistance.

Original languageEnglish
Pages (from-to)191-200
Number of pages10
JournalActa Medica Okayama
Volume68
Issue number4
Publication statusPublished - 2014

Fingerprint

Epidermal Growth Factor Receptor
Drug Resistance
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Cells
Pharmaceutical Preparations
Chemotherapy
Oncogenes
Disease-Free Survival
Research Personnel
Drug Therapy
Mutation

Keywords

  • Cancer stem cell
  • Drug resistance
  • EGFR mutation
  • Non-small cell lung cancer
  • Tyrosine-kinase inhibitor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. / Shiena, Kazuhiko; Yamamoto, Hiromasa; Sou, Junichi; Miyoshi, Shinichiro; Toyooka, Shinichi.

In: Acta Medica Okayama, Vol. 68, No. 4, 2014, p. 191-200.

Research output: Contribution to journalArticle

@article{1d0d2f3559c5444e907628f569fcd662,
title = "Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer",
abstract = "Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal growth factor receptor (EGFR) was defined as a clinically distinct molecular group. These lesions show oncogene addiction to EGFR and dramatic responses to the EGFR tyrosine kinase inhibitors (TKIs). Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy. However, the long-term effectiveness of EGFR-TKIs is usually limited because of acquired drug resistance. To overcome this resistance to EGFR-TKIs, it will be essential to identify the specific mechanisms underlying the resistance. Many investigators have attempted to identify the mechanisms using preclinical models and drug-resistant clinical samples. As a result, several mechanisms have been showed to be responsible for the resistance, but not all of the relevant mechanisms have been uncovered. In this review, we provide an overview of mechanisms underlying drug-resistance to EGFR-TKIs, focusing on results obtained with preclinical models, and we present some possible strategies to overcome the EGFR-TKI resistance.",
keywords = "Cancer stem cell, Drug resistance, EGFR mutation, Non-small cell lung cancer, Tyrosine-kinase inhibitor",
author = "Kazuhiko Shiena and Hiromasa Yamamoto and Junichi Sou and Shinichiro Miyoshi and Shinichi Toyooka",
year = "2014",
language = "English",
volume = "68",
pages = "191--200",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer

AU - Shiena, Kazuhiko

AU - Yamamoto, Hiromasa

AU - Sou, Junichi

AU - Miyoshi, Shinichiro

AU - Toyooka, Shinichi

PY - 2014

Y1 - 2014

N2 - Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal growth factor receptor (EGFR) was defined as a clinically distinct molecular group. These lesions show oncogene addiction to EGFR and dramatic responses to the EGFR tyrosine kinase inhibitors (TKIs). Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy. However, the long-term effectiveness of EGFR-TKIs is usually limited because of acquired drug resistance. To overcome this resistance to EGFR-TKIs, it will be essential to identify the specific mechanisms underlying the resistance. Many investigators have attempted to identify the mechanisms using preclinical models and drug-resistant clinical samples. As a result, several mechanisms have been showed to be responsible for the resistance, but not all of the relevant mechanisms have been uncovered. In this review, we provide an overview of mechanisms underlying drug-resistance to EGFR-TKIs, focusing on results obtained with preclinical models, and we present some possible strategies to overcome the EGFR-TKI resistance.

AB - Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal growth factor receptor (EGFR) was defined as a clinically distinct molecular group. These lesions show oncogene addiction to EGFR and dramatic responses to the EGFR tyrosine kinase inhibitors (TKIs). Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy. However, the long-term effectiveness of EGFR-TKIs is usually limited because of acquired drug resistance. To overcome this resistance to EGFR-TKIs, it will be essential to identify the specific mechanisms underlying the resistance. Many investigators have attempted to identify the mechanisms using preclinical models and drug-resistant clinical samples. As a result, several mechanisms have been showed to be responsible for the resistance, but not all of the relevant mechanisms have been uncovered. In this review, we provide an overview of mechanisms underlying drug-resistance to EGFR-TKIs, focusing on results obtained with preclinical models, and we present some possible strategies to overcome the EGFR-TKI resistance.

KW - Cancer stem cell

KW - Drug resistance

KW - EGFR mutation

KW - Non-small cell lung cancer

KW - Tyrosine-kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84906732620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906732620&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 191

EP - 200

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -